The Utility of Psilocybin in Managing Anxiety and Depression in Cancer Patients - Chu Hsien Lim; Brian D. Kangas; Jack Bergman (Biochemistry and Molecular Biology Education, 2018)

Psychedelics as anti-inflammatory agents. - Flanagan TW; Nichols CD (International review of psychiatry (Abingdon, England), 2018)

Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. - Ross S (International review of psychiatry (Abingdon, England), 2018)

Psychedelics and music: neuroscience and therapeutic implications. - Barrett FS; Preller KH; Kaelen M (International review of psychiatry (Abingdon, England), 2018)

Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy. - Hendricks PS (International review of psychiatry (Abingdon, England), 2018)

Current perspectives on psychedelic therapy: use of serotonergic hallucinogens in clinical interventions. - Garcia-Romeu A; Richards WA (International review of psychiatry (Abingdon, England), 2018)

Altered trajectories in the dynamical repertoire of functional network states under psilocybin - Lord L; Expert P; Atasoy S; Roseman L; Rapuano K; Lambiotte R; Nutt DJ; Deco G; Carhart-Harris RL; Kringelbach ML; Cabral J. (bioRxiv, 2018)

Convergent evolution of psilocybin biosynthesis by psychedelic mushrooms - Awan AR; Winter JM; Turner D; Shaw WM; Suz LM; Bradshaw AJ; Ellis T; Dentinger BT. (bioRxiv, 2018)

Psychoactive plant- and mushroom-associated alkaloids from two behavior modifying cicada pathogens - Boyce GR; Gluck-Thaler E; Slot JC; Stajich JE; Davis WJ; James TY; Cooley JR; Panaccione DG; Eilenberg J; Licht HHDF; Macias AM; Berger MC; et al. (bioRxiv, 2018)

Psychopharmacology of Psilocybin in Cancer Patients - Johns Hopkins University (ClinicalTrials.gov, 2018)

Biocatalytic Production of Psilocybin and Derivatives in Tryptophan Synthase-Enhanced Reactions. - Blei F; Baldeweg F; Fricke J; Hoffmeister D (Chemistry (Weinheim an der Bergstrasse, Germany), 2018)

Increased nature relatedness and decreased authoritarian political views after psilocybin for treatment-resistant depression. - Lyons T; Carhart-Harris RL (Journal of psychopharmacology (Oxford, England), 2018)

Psychedelic use and intimate partner violence: The role of emotion regulation. - Thiessen MS; Walsh Z; Bird BM; Lafrance A (Journal of psychopharmacology (Oxford, England), 2018)

Facile assembly and fluorescence-based screening method for heterologous expression of biosynthetic pathways in fungi. - Hoefgen S; Lin J; Fricke J; Stroe MC; Mattern DJ; Kufs JE; Hortschansky P; Brakhage AA; Hoffmeister D; Valiante V (Metabolic engineering, 2018)

Psychedelic therapy for smoking cessation: Qualitative analysis of participant accounts. - Noorani T; Garcia-Romeu A; Swift TC; Griffiths RR; Johnson MW (Journal of psychopharmacology (Oxford, England), 2018)

High dose psilocybin is associated with positive subjective effects in healthy volunteers. - Nicholas CR; Henriquez KM; Gassman MC; Cooper KM; Muller D; Hetzel S; Brown RT; Cozzi NV; Thomas C; Hutson PR (Journal of psychopharmacology (Oxford, England), 2018)

[Trends in Abuse of Biogenic Drugs in Parts of Germany 2007-2013]. - Pietsch J; Scheffel K; Acquarone D; Koch I; Deters M; Hermanns-Clausen M (Gesundheitswesen (Bundesverband der Arzte des Offentlichen Gesundheitsdienstes (Germany)), 2018)

Out of the box: A psychedelic model to study the creative mind. - Kuypers KPC (Medical hypotheses, 2018)

Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. - Grimm O; Kraehenmann R; Preller KH; Seifritz E; Vollenweider FX (European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2018)

Psilocybin and MDMA reduce costly punishment in the Ultimatum Game. - Gabay AS; Carhart-Harris RL; Mazibuko N; Kempton MJ; Morrison PD; Nutt DJ; Mehta MA (Scientific reports, 2018)

Analysis of new psychoactive substances in oral fluids by means of microextraction by packed sorbent followed by ultra-high-performance liquid chromatography-tandem mass spectrometry. - Rocchi R; Simeoni MC; Montesano C; Vannutelli G; Curini R; Sergi M; Compagnone D (Drug testing and analysis, 2018)

Lysergic acid diethylamide and psilocybin for the management of patients with persistent pain: a potential role? - Whelan A; Johnson MI (Pain management, 2018)

T263. Psilocybin Improves Cognitive Control and Downregulates Parietal Cortex in Treatment-Seeking Smokers - Michael C. McKenna; John R. Fedota; Albert Garcia-Romeu; Matthew R. Johnson; Roland R. Griffiths; Elliot A. Stein (Biological Psychiatry, 2018)

Psychedelic Drugs as Therapeutics: No Illusions About the Challenges. - Sellers EM; Leiderman DB (Clinical pharmacology and therapeutics, 2018)

Taking Psychedelics Seriously. - Byock I (Journal of palliative medicine, 2018)

Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. - Carrillo F; Sigman M; Fernández Slezak D; Ashton P; Fitzgerald L; Stroud J; Nutt DJ; Carhart-Harris RL (Journal of affective disorders, 2018)

Relief from intractable phantom pain by combining psilocybin and mirror visual-feedback (MVF). - Ramachandran V; Chunharas C; Marcus Z; Furnish T; Lin A (Neurocase, 2018)

Horizontal gene cluster transfer increased hallucinogenic mushroom diversity. - Reynolds HT; Vijayakumar V; Gluck-Thaler E; Korotkin HB; Matheny PB; Slot JC (Evolution letters, 2018)

Alteration of Depressive-like Behaviors by Psilocybe cubensis Alkaloid Extract in Mice: the Role of Glutamate Pathway - Elaheh Mahmoudi; Mehrdad Faizi; Reza Hajiaghaee; Ali Razmi (DOAJ (DOAJ: Directory of Open Access Journals), 2018)

Visual hallucinations and lifetime use of hallucinogen perception persisting disorder associated recreational drugs: results from a large online survey - Mascha M.J. Linszen; Hidde Kleijer; Iris E. Sommer (European Neuropsychopharmacology, 2018)

Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. - Reiche S; Hermle L; Gutwinski S; Jungaberle H; Gasser P; Majić T (Progress in neuro-psychopharmacology & biological psychiatry, 2018)

The 21st century psychedelic renaissance: heroic steps forward on the back of an elephant. - Sessa B (Psychopharmacology, 2018)

Psilocybin with psychological support improves emotional face recognition in treatment-resistant depression. - Stroud JB; Freeman TP; Leech R; Hindocha C; Lawn W; Nutt DJ; Curran HV; Carhart-Harris RL (Psychopharmacology, 2018)

Double-blind comparison of the two hallucinogens psilocybin and dextromethorphan: similarities and differences in subjective experiences. - Carbonaro TM; Johnson MW; Hurwitz E; Griffiths RR (Psychopharmacology, 2018)

Psilocybin with psychological support for treatment-resistant depression: six-month follow-up. - Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; et al. (Psychopharmacology, 2018)

Psilocybin disrupts sensory and higher order cognitive processing but not pre-attentive cognitive processing-study on P300 and mismatch negativity in healthy volunteers. - Bravermanová A; Viktorinová M; Tylš F; Novák T; Androvičová R; Korčák J; Horáček J; Balíková M; Griškova-Bulanova I; Danielová D; Vlček P; Mohr P; et al. (Psychopharmacology, 2018)

The hidden therapist: evidence for a central role of music in psychedelic therapy. - Kaelen M; Giribaldi B; Raine J; Evans L; Timmerman C; Rodriguez N; Roseman L; Feilding A; Nutt D; Carhart-Harris R (Psychopharmacology, 2018)

Can psychedelic drug help with depression? - Jessica Hamzelou (The New Scientist, 2018)

Taking Psychedelics Seriously (TH316) - Ira Byock; Charles S. Grob (Journal of Pain and Symptom Management, 2018)

ANALISIS SENYAWA HALUSINOGEN DALAM MINUMAN MAGIC MUSHROOM (Psilocybin baeocystis) YANG BEREDAR DI KAWASAN KUTA-BALI - N. M. Uaniti; O. O. Ratnayani; S. A. Sari (Jurnal Kimia, 2018)

The Experience Elicited by Hallucinogens Presents the Highest Similarity to Dreaming within a Large Database of Psychoactive Substance Reports - Camila Sanz; Federico Zamberlán; Earth Erowid; Fire Erowid; Enzo Tagliazucchi (Frontiers in Neuroscience, 2018)

The theory and practice of psilocybin assisted psychotherapy: an intervention design checklist - Volodymyr Mykhalevych (Työväentutkimus Vuosikirja, 2018)

Unlearning to See: Linking the Perceptual and Clinical Effects of Psychedelic Drugs. - Link Swanson (Cognitive Science, 2018)

Are psychedelics effective in treating anxiety associated with a lifethreatening disease - Kayla Wilwohl (Digital Commons - PCOM (Philadelphia College of Osteopathic Medicine), 2018)

Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Psychological Distress - Thomas Cody Swift (Western CEDAR (Western Washington University), 2018)

Psychedelics, the Spiritual and Consciousness-an Evolving Confluence in the Cultural Stream - Phil Wolfson (Tikkun, 2018)

Integration and segregation in whole-brain networks: implications for altered states of consciousness - Lord L. (University of Oxford, 2018)

Serotonergic Hallucinogen-Induced Visual Perceptual Alterations. - Kometer M; Vollenweider FX (Current topics in behavioral neurosciences, 2018)

Phenomenology, Structure, and Dynamic of Psychedelic States. - Preller KH; Vollenweider FX (Current topics in behavioral neurosciences, 2018)

Effect of Hallucinogens on Unconditioned Behavior. - Halberstadt AL; Geyer MA (Current topics in behavioral neurosciences, 2018)

Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates. - Barrett FS; Griffiths RR (Current topics in behavioral neurosciences, 2018)

Therapeutic Applications of Classic Hallucinogens. - Bogenschutz MP; Ross S (Current topics in behavioral neurosciences, 2018)

The Effects of Hallucinogens on Gene Expression. - Martin DA; Nichols CD (Current topics in behavioral neurosciences, 2018)

Hallucinogens and Serotonin 5-HT Receptor-Mediated Signaling Pathways. - López-Giménez JF; González-Maeso J (Current topics in behavioral neurosciences, 2018)

Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors. - Griffiths RR; Johnson MW; Richards WA; Richards BD; Jesse R; MacLean KA; Barrett FS; Cosimano MP; Klinedinst MA (Journal of psychopharmacology (Oxford, England), 2018)

The relationships of classic psychedelic use with criminal behavior in the United States adult population. - Hendricks PS; Crawford MS; Cropsey KL; Copes H; Sweat NW; Walsh Z; Pavela G (Journal of psychopharmacology (Oxford, England), 2018)

Novel psychotherapeutics - a cautiously optimistic focus on Hallucinogens. - Sherwood AM; Prisinzano TE (Expert review of clinical pharmacology, 2018)

Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. - Canal CE (Handbook of experimental pharmacology, 2018)

Advances and challenges in neuroimaging studies on the effects of serotonergic hallucinogens: Contributions of the resting brain. - Müller F; Liechti ME; Lang UE; Borgwardt S (Progress in brain research, 2018)

d-Lysergic acid diethylamide, psilocybin, and other classic hallucinogens: Mechanism of action and potential therapeutic applications in mood disorders. - De Gregorio D; Enns JP; Nuñez NA; Posa L; Gobbi G (Progress in brain research, 2018)

Common neural signatures of psychedelics: Frequency-specific energy changes and repertoire expansion revealed using connectome-harmonic decomposition. - Atasoy S; Vohryzek J; Deco G; Carhart-Harris RL; Kringelbach ML (Progress in brain research, 2018)

Clinical Interpretations of Patient Experience in a Trial of Psilocybin-Assisted Psychotherapy for Alcohol Use Disorder. - Bogenschutz MP; Podrebarac SK; Duane JH; Amegadzie SS; Malone TC; Owens LT; Ross S; Mennenga SE (Frontiers in pharmacology, 2018)

The Psychedelic Debriefing in Alcohol Dependence Treatment: Illustrating Key Change Phenomena through Qualitative Content Analysis of Clinical Sessions. - Nielson EM; May DG; Forcehimes AA; Bogenschutz MP (Frontiers in pharmacology, 2018)

"Hallucinations" Following Acute Cannabis Dosing: A Case Report and Comparison to Other Hallucinogenic Drugs. - Barrett FS; Schlienz NJ; Lembeck N; Waqas M; Vandrey R (Cannabis and cannabinoid research, 2018)

Unifying Theories of Psychedelic Drug Effects. - Swanson LR (Frontiers in pharmacology, 2018)

Individual Experiences in Four Cancer Patients Following Psilocybin-Assisted Psychotherapy. - Malone TC; Mennenga SE; Guss J; Podrebarac SK; Owens LT; Bossis AP; Belser AB; Agin-Liebes G; Bogenschutz MP; Ross S (Frontiers in pharmacology, 2018)

Biological Effects and Biodistribution of Bufotenine on Mice. - Vigerelli H; Sciani JM; Eula MAC; Sato LA; Antoniazzi MM; Jared C; Pimenta DC (BioMed research international, 2018)

Mushroom poisoning epidemiology in the United States. - Brandenburg WE; Ward KJ (Mycologia, 2018)

Hallucinogen persisting perception disorder: A literature review and three case reports. - Skryabin VY; Vinnikova M; Nenastieva A; Alekseyuk V (Journal of addictive diseases, 2018)

Psilocybin and Mental Health-Don't Lose Control. - Barnby JM; Mehta MA (Frontiers in psychiatry, 2018)

Psychedelic-Assisted Psychotherapy: A Paradigm Shift in Psychiatric Research and Development. - Schenberg EE (Frontiers in pharmacology, 2018)

Psychedelics, Meditation, and Self-Consciousness. - Millière R; Carhart-Harris RL; Roseman L; Trautwein FM; Berkovich-Ohana A (Frontiers in psychology, 2018)

Dimensions of consciousness and the psychedelic state. - Bayne T; Carter O (Neuroscience of consciousness, 2018)

More Realistic Forecasting of Future Life Events After Psilocybin for Treatment-Resistant Depression. - Lyons T; Carhart-Harris RL (Frontiers in psychology, 2018)

Intensity of Mystical Experiences Occasioned by 5-MeO-DMT and Comparison With a Prior Psilocybin Study. - Barsuglia J; Davis AK; Palmer R; Lancelotta R; Windham-Herman AM; Peterson K; Polanco M; Grant R; Griffiths RR (Frontiers in psychology, 2018)

Rapid-Acting Antidepressants. - Witkin JM; Knutson DE; Rodriguez GJ; Shi S (Current pharmaceutical design, 2018)

Mikrodosering av lysergsyradietylamid och psilocybin och dess effekter på psykisk hälsa - Anisha Lela Larsson (KTH Publication Database DiVA (KTH Royal Institute of Technology), 2017)

If you give a mouse a mushroom: Behavioral effects of hallucinogens in mice - Landon M. Klein (eScholarship (California Digital Library), 2017)

Psilocybin and Depression - Assessing the Long-term Effects of a Single Administration of Psilocybin on the Psychiatric Symptoms and Brain Activity of Patients With Severe Depression - University of Helsinki (ClinicalTrials.gov, 2017)

„Terapia szokowa”, czyli agoniści receptor 5-HT2A w leczeniu depresji i lęku - Joanna Stefaniuk (CeON Repository (Centre for Evaluation in Education and Science), 2017)

Pharmacokinetics of Escalating Doses of Oral Psilocybin in Healthy Adults. - Brown RT; Nicholas CR; Cozzi NV; Gassman MC; Cooper KM; Muller D; Thomas CD; Hetzel SJ; Henriquez KM; Ribaudo AS; Hutson PR (Clinical pharmacokinetics, 2017)

Can Psilocybin Treat Severe Depression - Barbara Geller (Journal watch, 2017)

Psychedelic Medicine for Mental Illness and Substance Use Disorders: Overcoming Social and Legal Obstacles - Mason Marks (SSRN Electronic Journal, 2017)

Psychedelic Drugs in Biomedicine. - Kyzar EJ; Nichols CD; Gainetdinov RR; Nichols DE; Kalueff AV (Trends in pharmacological sciences, 2017)

Neuroticism is associated with challenging experiences with psilocybin mushrooms. - Barrett FS; Johnson MW; Griffiths RR (Personality and individual differences, 2017)

Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. - Carhart-Harris RL; Roseman L; Bolstridge M; Demetriou L; Pannekoek JN; Wall MB; Tanner M; Kaelen M; McGonigle J; Murphy K; Leech R; Curran HV; et al. (Scientific reports, 2017)

Pharmacokinetics and Pharmacodynamics of Lysergic Acid Diethylamide in Healthy Subjects. - Dolder PC; Schmid Y; Steuer AE; Kraemer T; Rentsch KM; Hammann F; Liechti ME (Clinical pharmacokinetics, 2017)

The Therapeutic Potential of Psychedelic Drugs: Past, Present, and Future. - Carhart-Harris RL; Goodwin GM (Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2017)

Psilocybin: Good Trip or Bad Trip. - Sellers EM (Clinical pharmacology and therapeutics, 2017)

LSD treatment in Scandinavia: emphasizing indications and short-term treatment outcomes of 151 patients in Denmark. - Larsen JK (Nordic journal of psychiatry, 2017)

Two dose investigation of the 5-HT-agonist psilocybin on relative and global cerebral blood flow. - Lewis CR; Preller KH; Kraehenmann R; Michels L; Staempfli P; Vollenweider FX (NeuroImage, 2017)

Enzymatic Synthesis of Psilocybin. - Fricke J; Blei F; Hoffmeister D (Angewandte Chemie (International ed. in English), 2017)

Google Trends Analyses and Case Report: A Persistently Dilated Pupil in Psychedelics’ User - Ahmed Al-Imam (Global Journal of Health Science, 2017)

Psychoactive substances as a last resort-a qualitative study of self-treatment of migraine and cluster headaches. - Andersson M; Persson M; Kjellgren A (Harm reduction journal, 2017)

Effect of Psilocybin on Empathy and Moral Decision-Making. - Pokorny T; Preller KH; Kometer M; Dziobek I; Vollenweider FX (The international journal of neuropsychopharmacology, 2017)

‘Magic mushroom’ enzyme mystery solved - STEVE RITTER (C&EN Global Enterprise, 2017)

NATURALIZING PSYCHEDELIC SPIRITUALITY - Chris Letheby (Zygon®, 2017)

Horizontal gene cluster transfer increased hallucinogenic mushroom diversity - Reynolds HT; Vijayakumar V; Gluck-Thaler E; Korotkin HB; Matheny PB; Slot JC. (bioRxiv, 2017)

Enzymatische Synthese von Psilocybin - Janis Fricke; Felix Blei; Dirk Hoffmeister (Angewandte Chemie, 2017)

[New patterns of substance use and abuse among French adolescents, a knowledge synthesis]. - Jeanne G; Purper-Ouakil D; Rigole H; Franc N (L'Encephale, 2017)

Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness. - Forstmann M; Sagioglou C (Journal of psychopharmacology (Oxford, England), 2017)

Proposal of 5-methoxy-N-methyl-N-isopropyltryptamine consumption biomarkers through identification of in vivo metabolites from mice. - Fabregat-Safont D; Barneo-Muñoz M; Martinez-Garcia F; Sancho JV; Hernández F; Ibáñez M (Journal of chromatography. A, 2017)

Psilocybin and Mescaline - Molecule of the Month October 1999 [Archived version] - Paul May (Bristol Research (University of Bristol), 2017)

Navigating Psychedelic Medicines through (Inter)national Regulation - Jonathan Nash (Northumbria Research Link (Northumbria University), 2017)

An online survey of tobacco smoking cessation associated with naturalistic psychedelic use. - Johnson MW; Garcia-Romeu A; Johnson PS; Griffiths RR (Journal of psychopharmacology (Oxford, England), 2017)

Potential Therapeutic Effects of Psilocybin. - Johnson MW; Griffiths RR (Neurotherapeutics: the journal of the American Society for Experimental NeuroTherapeutics, 2017)

[Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges]. - Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J (Fortschritte der Neurologie-Psychiatrie, 2017)

New psychoactive substances of natural origin: A brief review. - Feng LY; Battulga A; Han E; Chung H; Li JH (Journal of food and drug analysis, 2017)

Developing Guidelines and Competencies for the Training of Psychedelic Therapists - Janis Phelps (Journal of Humanistic Psychology, 2017)

Patients’ Accounts of Increased “Connectedness” and “Acceptance” After Psilocybin for Treatment-Resistant Depression - Rosalind Watts; Camilla Day; Jacob Krzanowski; David Nutt; Robin Carhart-Harris (Journal of Humanistic Psychology, 2017)

Psilocybin-assisted therapy for anxiety and depression: implications for euthanasia. - Strauss N (The Medical journal of Australia, 2017)

Cancer at the Dinner Table: Experiences of Psilocybin-Assisted Psychotherapy for the Treatment of Cancer-Related Distress - Thomas Cody Swift; Alexander Belser; Gabrielle Agin-Liebes; Neşe Devenot; Sara Terrana; Harris L. Friedman; Jeffrey Guss; Anthony P. Bossis; Stephen Ross (Journal of Humanistic Psychology, 2017)

The Effects of LSD and Psilocin on Anxiety-Related Behaviours in Zebrafish - Anne Walley (Student Research Proceedings, 2017)

Alterations of consciousness and mystical-type experiences after acute LSD in humans. - Liechti ME; Dolder PC; Schmid Y (Psychopharmacology, 2017)

Patient Experiences of Psilocybin-Assisted Psychotherapy: An Interpretative Phenomenological Analysis - Alexander Belser; Gabrielle Agin-Liebes; Thomas Cody Swift; Sara Terrana; Neşe Devenot; Harris L. Friedman; Jeffrey Guss; Anthony P. Bossis; Stephen Ross (Journal of Humanistic Psychology, 2017)

Increased spontaneous MEG signal diversity for psychoactive doses of ketamine, LSD and psilocybin. - Schartner MM; Carhart-Harris RL; Barrett AB; Seth AK; Muthukumaraswamy SD (Scientific reports, 2017)

Should addiction researchers be interested in psychedelic science? - Stephen Bright; M.L. Williams; David Caldicott (Drug and Alcohol Review, 2017)

The Development and Regulation of Psychedelic Medicines - Jonathan Nash (Northumbria Research Link (Northumbria University), 2017)

Anti-inflammatory effects of serotonin 5-HT2A receptor activation in ovalbumin-induced allergic asthma models - Thomas W. Flanagan; Melaine N. Sebastian; Charles D. Nichols (The FASEB Journal, 2017)

Ayahuasca, dimethyltryptamine, and psychosis: a systematic review of human studies. - Dos Santos RG; Bouso JC; Hallak JEC (Therapeutic advances in psychopharmacology, 2017)

No clinically relevant effects in children after accidental ingestion of Panaeolina foenisecii (lawn mower's mushroom). - Schenk-Jaeger KM; Hofer-Lentner KE; Plenert B; Eckart D; Haberl B; Schulze G; Borchert-Avalone J; Stedtler U; Pfab R (Clinical toxicology (Philadelphia, Pa.), 2017)

The fibrinolytic system: A new target for treatment of depression with psychedelics. - Idell RD; Florova G; Komissarov AA; Shetty S; Girard RB; Idell S (Medical hypotheses, 2017)

Psilocybin for treating substance use disorders? - de Veen BT; Schellekens AF; Verheij MM; Homberg JR (Expert review of neurotherapeutics, 2017)

Psychedelics as Medicines: An Emerging New Paradigm. - Nichols DE; Johnson MW; Nichols CD (Clinical pharmacology and therapeutics, 2017)

Designer Drugs 2.0. - Huestis MA; Tyndale RF (Clinical pharmacology and therapeutics, 2017)

Comparison of anomalous experiences after ingesting psilocybin mushrooms in research and non-research settings - Theresa M. Carbonaro; Matthew W. Johnson; Roland R. Griffiths (Drug and Alcohol Dependence, 2017)

Psilocybin in long-term meditators: Effects on default mode network functional connectivity and retrospective ratings of qualitative experience - Frederick S. Barrett; Matthew W. Johnson; Roland R. Griffiths (Drug and Alcohol Dependence, 2017)

Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance - Dinis-Oliveira Ricardo Jorge (Drug Metabolism Reviews, 2017)

Psilocybin and Mescaline - Molecule of the Month October 1999 [Archived version] - Paul May (Open MIND, 2017)

A New Spectrophotometric Method for the Determination of Psilocin and Psilocybin - Krishna Lavanya; T.R. Baggi (International Journal of Analytical and Applied Chemistry, 2017)

Sex Differences in Serotonergic and Dopaminergic Mediation of LSD Discrimination in Rats - Keli A. Herr (ScholarWorks - WMU (Western Michigan University), 2017)

Maddening Therapies: How Hallucinogens Morphed into Novel Treatments - Henry A. Nasrallah (Current psychiatry, 2017)

Narrative therapy-assisted psilocybin use for treatment of depression - Carlyn Delavan (Seattle Pacific University Research Conference, 2017)

Simultaneous determination of γ-hydroxybutyric acid, ibotenic acid and psilocybin in saliva samples by capillary electrophoresis coupled with a contactless conductivity detector - Piret Saar-Reismaa; Merike Vaher; Mihkel Kaljurand; Maria Kulp; Jekaterina Mazina-Šinkar (Analytical Methods, 2017)

Neuronal dynamics of the anterior cingulate cortex during working memory and serotonergic manipulation - Golden C. (Imperial College London, 2017)

Long-term follow-up of psilocybin-facilitated smoking cessation. - Johnson MW; Garcia-Romeu A; Griffiths RR (The American journal of drug and alcohol abuse, 2017)

It's time to take psilocybin seriously as a possible treatment for substance use disorders. - Bogenschutz MP (The American journal of drug and alcohol abuse, 2017)

Statistical comparison of mass spectra for identification of amphetamine-type stimulants. - Bodnar Willard MA; McGuffin VL; Smith RW (Forensic science international, 2017)

Challenges in Laboratory Detection of Unusual Substance Abuse: Issues with Magic Mushroom, Peyote Cactus, Khat, and Solvent Abuse. - Dasgupta A (Advances in clinical chemistry, 2017)

Role of psilocybin in the treatment of depression. - Mahapatra A; Gupta R (Therapeutic advances in psychopharmacology, 2017)

Dreams and Psychedelics: Neurophenomenological Comparison and Therapeutic Implications. - Kraehenmann R (Current neuropharmacology, 2017)

Could Hallucinogens Induce Permanent Pupillary Changes in (Ab)users? A Case Report from New Zealand. - Al-Imam A (Case reports in neurological medicine, 2017)

Self unbound: ego dissolution in psychedelic experience. - Letheby C; Gerrans P (Neuroscience of consciousness, 2017)

Qualitative and Quantitative Features of Music Reported to Support Peak Mystical Experiences during Psychedelic Therapy Sessions. - Barrett FS; Robbins H; Smooke D; Brown JL; Griffiths RR (Frontiers in psychology, 2017)

Psilocybin-Assisted Therapy: A Review of a Novel Treatment for Psychiatric Disorders. - Thomas K; Malcolm B; Lastra D (Journal of psychoactive drugs, 2017)

LSD Increases Primary Process Thinking via Serotonin 2A Receptor Activation. - Kraehenmann R; Pokorny D; Aicher H; Preller KH; Pokorny T; Bosch OG; Seifritz E; Vollenweider FX (Frontiers in pharmacology, 2017)

The "Endless Trip" among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. - Orsolini L; Papanti GD; De Berardis D; Guirguis A; Corkery JM; Schifano F (Frontiers in psychiatry, 2017)

Quality of Acute Psychedelic Experience Predicts Therapeutic Efficacy of Psilocybin for Treatment-Resistant Depression. - Roseman L; Nutt DJ; Carhart-Harris RL (Frontiers in pharmacology, 2017)

Clinical potential of psilocybin as a treatment for mental health conditions. - Daniel J; Haberman M (The mental health clinician, 2017)

Lysergsyradietylamid (LSD) och psilocybin vid depression och ångestsjukdom: En litteraturstudie om effekter och biverkningar av LSD- och psilocybin-assisterad psykoterapi - Natalie Engström (KTH Publication Database DiVA (KTH Royal Institute of Technology), 2016)

Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences. - Carbonaro TM; Bradstreet MP; Barrett FS; MacLean KA; Jesse R; Johnson MW; Griffiths RR (Journal of psychopharmacology (Oxford, England), 2016)

Classical hallucinogens and neuroimaging: A systematic review of human studies: Hallucinogens and neuroimaging. - Dos Santos RG; Osório FL; Crippa JAS; Hallak JEC (Neuroscience and biobehavioral reviews, 2016)

The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms. - Barrett FS; Bradstreet MP; Leoutsakos JS; Johnson MW; Griffiths RR (Journal of psychopharmacology (Oxford, England), 2016)

Psychedelics in the treatment of unipolar mood disorders: a systematic review. - Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH (Journal of psychopharmacology (Oxford, England), 2016)

Psilocybin for anxiety and depression in cancer care? Lessons from the past and prospects for the future. - Nutt D (Journal of psychopharmacology (Oxford, England), 2016)

Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. - Ross S; Bossis A; Guss J; Agin-Liebes G; Malone T; Cohen B; Mennenga SE; Belser A; Kalliontzi K; Babb J; Su Z; Corby P; et al. (Journal of psychopharmacology (Oxford, England), 2016)

Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. - Griffiths RR; Johnson MW; Carducci MA; Umbricht A; Richards WA; Richards BD; Cosimano MP; Klinedinst MA (Journal of psychopharmacology (Oxford, England), 2016)

Psilocybin: Psychotherapy or drug? - Goodwin GM (Journal of psychopharmacology (Oxford, England), 2016)

Psilocybin in end of life care: Implications for further research. - Summergrad P (Journal of psychopharmacology (Oxford, England), 2016)

Psilocybin and palliative end-of-life care. - Shelton RC; Hendricks PS (Journal of psychopharmacology (Oxford, England), 2016)

Psilocybin for depression and anxiety associated with life-threatening illnesses. - McCorvy JD; Olsen RH; Roth BL (Journal of psychopharmacology (Oxford, England), 2016)

The role of psychedelics in palliative care reconsidered: A case for psilocybin. - Kelmendi B; Corlett P; Ranganathan M; D'Souza C; Krystal JH (Journal of psychopharmacology (Oxford, England), 2016)

Psilocybin-assisted psychotherapy for dying cancer patients - aiding the final trip. - Spiegel D (Journal of psychopharmacology (Oxford, England), 2016)

Psilocybin: promising results in double-blind trials require confirmation by real-world evidence. - Breckenridge A; Grobbee DE (Journal of psychopharmacology (Oxford, England), 2016)

Return of the psychedelics: Psilocybin for treatment resistant depression. - Patra S (Asian journal of psychiatry, 2016)

Tripping up addiction: the use of psychedelic drugs in the treatment of problematic drug and alcohol use - Celia J. A. Morgan; Amy McAndrew; Tobias Stevens; David Nutt; Will Lawn (Current Opinion in Behavioral Sciences, 2016)

Development of a Psychotherapeutic Model for Psilocybin-Assisted Treatment of Alcoholism - Michael P. Bogenschutz; Alyssa A. Forcehimes (Journal of Humanistic Psychology, 2016)

Psilocybin-induced psychosis in humans and in rats − translational quantitative EEG study - Filip Tylš; Čestmír Vejmola; Michaela Viktorinová; L. Kadeřábek; Tomáš Páleníček (European Neuropsychopharmacology, 2016)

Psilocybin-induced decrease in amygdala-putamen coupling during an event-related face discrimination task - O. Grimm; Rainer Krähenmann; Katrin H. Preller; Erich Seifritz; F.X. Vollenweider (European Neuropsychopharmacology, 2016)

Exploring Hallucinogen Pharmacology and Psychedelic Medicine with Zebrafish Models. - Kyzar EJ; Kalueff AV (Zebrafish, 2016)

Psilocybin as an alternative medicine for patients suffering from depression - Karolina Dydak; Mariola Śliwińska-Mossoń; Halina Milnerowicz (Psychiatria i Psychologia Kliniczna, 2016)

Psychedelic Psychotherapy: Insights From 25 Years of Research - William A. Richards (Journal of Humanistic Psychology, 2016)

Psilocybin: panacea or placebo? - Hendrie C; Pickles A (The lancet. Psychiatry, 2016)

Question-based Drug Development for psilocybin. - Dijkstra FM; Jacobs GE; Cohen AF (The lancet. Psychiatry, 2016)

Question-based Drug Development for psilocybin - Authors' reply. - Carhart-Harris RL; Nutt DJ (The lancet. Psychiatry, 2016)

Hallucinogen Persistent Perception Disorder Induced by New Psychoactive Substituted Phenethylamines; A Review with Illustrative Case - Cornel N. Stanciu; Thomas M. Penders (Current Psychiatry Reviews, 2016)

Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens. - Rickli A; Moning OD; Hoener MC; Liechti ME (European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2016)

Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. - Carhart-Harris RL; Bolstridge M; Rucker J; Day CM; Erritzoe D; Kaelen M; Bloomfield M; Rickard JA; Forbes B; Feilding A; Taylor D; Pilling S; et al. (The lancet. Psychiatry, 2016)

Altered states: psilocybin for treatment-resistant depression. - Cowen P (The lancet. Psychiatry, 2016)

Hallucinogen Use Disorders. - Hardaway R; Schweitzer J; Suzuki J (Child and adolescent psychiatric clinics of North America, 2016)

Antidepressant, Antipsychotic, and Hallucinogen Drugs for the Treatment of Psychiatric Disorders: A Convergence at the Serotonin-2A Receptor. - Howland RH (Journal of psychosocial nursing and mental health services, 2016)

Naltrexone but Not Ketanserin Antagonizes the Subjective, Cardiovascular, and Neuroendocrine Effects of Salvinorin-A in Humans. - Maqueda AE; Valle M; Addy PH; Antonijoan RM; Puntes M; Coimbra J; Ballester MR; Garrido M; González M; Claramunt J; Barker S; Lomnicka I; et al. (The international journal of neuropsychopharmacology, 2016)

ChemInform Abstract: Observations Concerning the Synthesis of Tryptamine Homologues and Branched Tryptamine Derivatives via the Borrowing Hydrogen Process: Synthesis of Psilocin, Bufotenin, and Serotonin. - Bartolucci Silvia; Mari Michele; Di Gregorio Giovanni; Piersanti Giovanni (ChemInform, 2016)

MAGIC MUSHROOMS: from sacred entheogen to Class A drug - Charlotte Walsh (Entertainment and Sports Law Journal, 2016)

Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years. - Dos Santos RG; Osório FL; Crippa JA; Riba J; Zuardi AW; Hallak JE (Therapeutic advances in psychopharmacology, 2016)

Sex differences and serotonergic mechanisms in the behavioural effects of psilocin - Tylš Filip; Páleníček Tomáš; Kadeřábek Lukáš; Lipski Michaela; Kubešová Anna; Horáček Jiří (Behavioural Pharmacology, 2016)

DNA-based taxonomic identification of basidiospores in hallucinogenic mushrooms cultivated in “grow-kits” seized by the police: LC-UV quali-quantitative determination of psilocybin and psilocin - Gambaro Veniero; Roda Gabriella; Visconti Giacomo Luca; Arnoldi Sebastiano; Casagni Eleonora; Dell’Acqua Lucia; Farè Fiorenza; Paladino Eleonora; Rusconi Chiara; Arioli Stefania; Mora Diego (Journal of Pharmaceutical and Biomedical Analysis, 2016)

PM506. Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG - Tyls F; Michaela Viktorinova T; Prokopcova D; Korcak J; Androvicova R; Brunovsky M; Horacek J. (The international journal of neuropsychopharmacology, 2016)

PM502. Effect of psilocybin on EEG brain connectivity in healthy volunteers - preliminary report - Palenicek T; Tyls F; Viktorinova M; Prokopcova D; Korcak J; Androvicova R; Brunovsky M; Horacek J. (The international journal of neuropsychopharmacology, 2016)

PM502. Effect of psilocybin on EEG brain connectivity in healthy volunteers - preliminary report - Tomáš Páleníček; Filip Tylš; Michaela Viktorinová; Dominika Prokopcova; Jakub Korčák; Renata Androvičová; Martin Brunovský; Jiřı́ Horáček (The International Journal of Neuropsychopharmacology, 2016)

PM506. Psilocybin Clinical Trial: Acute Effects and its relationship to the brain activity as measured by quantitative EEG - Filip Tylš; Michaela Viktorinová; Dominika Prokopcova; Jakub Korčák; Renata Androvičová; Martin Brunovský; Jiřı́ Horáček (The International Journal of Neuropsychopharmacology, 2016)

A Phenomenological Examination of Psilocybin and its Positive and Persisting Aftereffects - Joseph A. Zamaria (NeuroQuantology, 2016)

Sixty seconds on... psilocybin. - Hawkes N (BMJ (Clinical research ed.), 2016)

On the Origin of the Genus Psilocybe and Its Potential Ritual Use in Ancient Africa and Europe1 - Tom Froese; Gastón Guzmán; Laura Guzmán-Dávalos (Economic Botany, 2016)

Effects of serotonin 2A/1A receptor stimulation on social exclusion processing. - Preller KH; Pokorny T; Hock A; Kraehenmann R; Stämpfli P; Seifritz E; Scheidegger M; Vollenweider FX (Proceedings of the National Academy of Sciences of the United States of America, 2016)

Novel psychopharmacological therapies for psychiatric disorders: psilocybin and MDMA. - Mithoefer MC; Grob CS; Brewerton TD (The lancet. Psychiatry, 2016)

Observations concerning the synthesis of tryptamine homologues and branched tryptamine derivatives via the borrowing hydrogen process: synthesis of psilocin, bufotenin, and serotonin - Bartolucci Silvia; Mari Michele; Di Gregorio Giovanni; Piersanti Giovanni (Tetrahedron, 2016)

Psychedelics. - Nichols DE (Pharmacological reviews, 2016)

Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience. - Pokorny T; Preller KH; Kraehenmann R; Vollenweider FX (European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology, 2016)

[Three cases of acute serotonin syndrome due to psilocybin mushroom poisoning]. - Suzuki K (Chudoku kenkyu: Chudoku Kenkyukai jun kikanshi = The Japanese journal of toxicology, 2016)